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ABSTRACT
The B cell-stimulating molecules, BAFF (B cell activating factor) and APRIL (a proliferation-inducing
ligand), are critical factors in the maintenance of the B cell pool and humoral immunity. In addition,
BAFF and APRIL are involved in the pathogenesis of a number of human autoimmune diseases, with
elevated levels of these cytokines detected in the sera of patients with systemic lupus erythematosus
(SLE), IgA nephropathy, Sjögren’s syndrome, and rheumatoid arthritis. As such, both molecules are
rational targets for new therapies in B cell-driven autoimmune diseases, and several inhibitors of BAFF
or BAFF andAPRIL together havebeen investigated in clinical trials. These include theBAFF/APRIL dual
inhibitor, atacicept, and the BAFF inhibitor, belimumab, which is approved as an add-on therapy for
patientswith active SLE.Posthoc analysesof these trials indicate thatbaseline serum levels of BAFFand
BAFF/APRIL correlate with treatment response to belimumab and atacicept, respectively, suggesting
a role for the two molecules as predictive biomarkers. It will, however, be important to refine future
testing to identify active forms of BAFF and APRIL in the circulation, as well as to distinguish between
homotrimer and heteromer configurations.
In this review, we discuss the rationale for dual BAFF/APRIL inhibition versus single BAFF inhibition in
autoimmune disease, by focusing on the similarities and differences between the physiological and
pathogenic roles of the two molecules. A summary of the preclinical and clinical data currently avail-
able is also presented.
Introduction
The B cell-stimulating molecules, BAFF (B cell activating
factor) and APRIL (a proliferation-inducing ligand), are
implicated in several human autoimmune diseases with
autoreactive B cell involvement, including systemic lupus
erythematosus (SLE) [1–10], IgA nephropathy (IgAN)
[11–13], Sjögren’s syndrome (SS) [14–16], and rheuma-
toid arthritis (RA) [17].
Members of the tumor necrosis factor (TNF) family,
to which BAFF and APRIL belong [18–20], are trimeric
molecules [19,21,22]. BAFF and APRIL bind to trans-
membrane activator and CAML interactor (TACI) and B
cell maturation antigen (BCMA), while BAFF addition-
ally binds to a third receptor, BAFF-R; all three recep-
tors are expressed by B lineage cells [23–28]. APRIL, but
not BAFF, can also bind heparan sulfate proteoglycans
(HSPG) within the extracellular matrix or on the sur-
face of cells such as plasma cells [29–32]. An overview of
the protein configurations of BAFF and APRIL, as well as
their receptors, can be seen in Figure 1.
CONTACT Eileen Samy, PhD, eileen.samy@emdserono.com EMD Serono Research & Development Institute, A Middlesex Turnpike, Billerica, MA, USA.
Color versions of one or more of the ﬁgures in the article can be found online at www.tandfonline.com/iiri
BAFF maintains B cell homeostasis by acting as a sur-
vival and fitness factor for B cells from the transitional
stage of development onwards, while APRIL appears to
act at a later stage, modulating the function and survival
of antigen-experienced B cells [23,33–36]. Both cytokines
stimulate class-switch recombination (CSR), hence con-
tribute to shaping humoral effector mechanisms. With
regards to humoral memory, APRIL is involved in the
establishment and survival of the long-lived plasma cell
(LLPC) pool in the bone marrow (BM) [37–46], whereas
the role of BAFF in this process is less clear [43]. Early
reports from preclinical experiments in the NZB/W F1
mouse model of SLE comparing BAFF, APRIL or dual
BAFF/APRIL blockade with BAFFR-Fc, an anti-APRIL
antibody, or TACI-Fc, respectively, support the notion
that BAFF and APRIL act in concert and at a flexible
degree of interchangeability to support humoral memory
via LLPC niche maintenance [47].
Elevated levels of BAFF and APRIL in the sera
of patients with certain autoimmune diseases correlate
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Figure . BAFF and APRIL receptor interactions. BAFF and APRIL are ﬁrst synthetized as type II transmembrane proteins that are mainly
expressed in cells ofmyeloid origin or stromal cells. They are processed to trimeric soluble cytokines by furin or furin-like protease(s). APRIL
and BAFF can also assemble as heteromers containing twoAPRIL and one BAFF, or two BAFF and one APRIL protomers. The three receptors
are type III transmembrane proteins (lacking signal peptides) mainly expressed by B cells at diﬀerent stages of diﬀerentiation and whose
main, but not exclusive function, is to provide survival and ﬁtness signals to cells. BAFF-R binds BAFF only, and to a lesser extent BAFF-
rich but not APRIL-rich heteromer. BAFF–BAFF-R interactions have a dominant role for the maintenance of the peripheral mature naïve
B cell pool. TACI binds to both BAFF and APRIL but responds better, if not exclusively, to oligomeric ligands (i.e. containing more than
one trimer: membrane-bound BAFF, BAFF -mer [containing  trimers] or heparan sulphate proteoglycan (HSPG)-bound APRIL). BCMA
binds to APRIL with higher aﬃnity than to BAFF. TACI can be cleaved by the ADAM metalloprotease to act as a soluble decoy receptor
that inhibits both BAFF and APRIL. BCMA can be processed by γ -secretase, releasing a soluble decoy receptor that, in its monomeric form
and because of its weak aﬃnity for BAFF, inhibits APRIL only.
with disease severity [2,3,7,10–12,16,48–51] and levels
of pathogenic autoantibodies [3-5,7,52,53], highlighting
these molecules as therapeutic targets. Compounds tar-
geting BAFF alone have been the subject of recent clin-
ical investigations, and the BAFF inhibitor, belimumab,
has been approved as add-on therapy for the treatment
of patients with seropositive SLE [54,55]. Compounds
inhibiting both BAFF and APRIL are being evaluated;
in particular, atacicept, which is currently undergoing
phase II clinical investigation for the treatment of patients
with moderate-to-severe SLE (completion of primary
analysis expected in 2016).
The aim of this review is to explore the potential
advantages and drawbacks of targeting BAFF and APRIL
together over BAFF alone by examining the biological
properties and physiological roles of both molecules, as
well as their respective roles in B cell-driven autoimmune
diseases. Up-to-date data from preclinical and clinical
studies of BAFF and APRIL antagonists will also be
presented.
Biological properties of BAFF and APRIL
Characterization and conﬁguration
BAFF, also known as BLyS (B Lymphocyte Stimulator),
was first characterized by its capacity to co-stimulate
B cell proliferation and induce immunoglobulin
production in vivo [19,20]. It is a type II membrane
protein that exists either in membrane-expressed or
soluble cytokine forms, both of which are capable of
eliciting B cell activation [19,20,56]. Soluble BAFF can
be released as a trimeric molecule, which in neutral
solution can combine to form 60-mers (20 trimers) via
interaction of a unique extended loop [57,58]. APRIL was
originally identified in the context of tumor cell growth
and defined by its capacity to induce the proliferation
of transformed cells in vitro [18]. Like BAFF, APRIL is
also a member of the TNF family, with soluble APRIL
and BAFF sharing ∼30% sequence identity [21]. Unlike
BAFF, the soluble form of which can be cleaved at the cell
surface [19], overexpression of APRIL in HEK 293T cells
indicates that APRIL is processed intracellularly in the
Golgi apparatus prior to secretion [59]. BAFF and APRIL
can also combine to form heteromers, which have been
detected in the sera of patients with rheumatic diseases
[60,61]. Heteromers can form either with two APRIL
molecules and one BAFF molecule (known as BAA), or
one APRIL molecule with two BAFF molecules (known
as ABB), the latter of which has been crystallized [62].
Receptor expression and interactions
BAFF binds its three receptors with different affinities: it
binds most strongly to BAFF-R, followed by TACI, and
binds (monomeric) BCMA rather weakly [63,64]. APRIL
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is the preferred ligand of BCMA, whereas TACI binds
to BAFF and APRIL with equal affinity [63–65]. BAFF
signaling through BAFF-R uses the NF-κB and PI3K
pathways [66–68], whereas APRIL signals through the
NF-κB pathway following binding to BCMA and TACI
[25–27]. APRIL also binds to HSPG both in the extra-
cellular matrix and on the surface of tumor or other cells
[29–32], triggering APRIL multimerization and enabling
signaling via TACI [32,44,69]. The heteromeric forms of
BAFF andAPRIL have distinct receptor binding specifici-
ties: both ABB and BAA bind to BCMA and TACI, but
only ABB binds to BAFF-R (with a weaker affinity com-
pared with BAFF – BAFF-R binding) [62].
BAFF-R, BCMA and TACI are expressed by B cells
at various stages of maturation and differentiation [28].
BAFF-R is already expressed by transitional B cells in
the BM, albeit at lower levels than on mature B cells,
such as naïve and memory B cells [70]. Notably, BAFF-R
expression by short-lived plasma cells is also reduced
compared with transitional B cells, and is absent from
long-lived BM plasma cells, suggesting that its expres-
sion may decline as B cells progress towards terminal
differentiation [28]. Both BCMA and TACI are expressed
by memory B cells and tonsillar germinal center B cells
[28,71], and in one study TACI was also detected on a
subpopulation of CD27-naïve B cells that expressed acti-
vation markers such as CD25 and CD80, suggesting that
TACI expression is induced upon B cell activation [28].
While BCMA is expressed by long-lived tonsillar and BM
plasma cells, the expression of TACI by tonsillar plasma
cells is less clear, with some investigators detecting it
[28,71], and others being unable to identify its expression
in this cell type [32].
Cellular expression
BAFF mRNA was initially detected in human periph-
eral blood mononuclear cells (PBMCs) within the spleen,
lymph nodes, and BM [19,20], and BAFF protein can
be found on the surface of cells of myeloid origin
[20]. Expression of BAFF can be induced in vitro, in
response to granulocyte-colony stimulating factor (G-
CSF), interferon-γ (IFNγ ), type I IFN, CD40-ligand,
lipopolysaccharide or interleukin-10 (IL-10), in both
human cell lines of myeloid origin, and cells isolated from
human peripheral blood (macrophages, dendritic cells
[DCs] and neutrophils) [20,37,56,72]. The upregulation
of low levels of BAFF transcription has also been observed
in T cells following T cell receptor stimulation [73].
Together, these initial findings have led to the percep-
tion that BAFF is primarily produced by cells of myeloid
lineage; however, investigations in BAFF-deficient BM
chimeric mice and mice immunized with T-dependent
antigen indicate that BAFF is also expressed by non-
hematopoietic cells, such as stromal cells [74].
Early studies detected APRIL mRNA expression in
tumor cell lines and human cancer cells of colon, thyroid,
and lymphoid origin [18]. It has since been shown that
APRIL is expressed by a number of myeloid-derived cell
types including BM granulocytes [45], megakaryocytes
[75,76], eosinophils [77] and osteoclasts [78,79], and
by dendritic cells following exposure to IFNα, IFNγ
or CD40L [37]. APRIL expression is induced during
hematopoiesis in the BM. Consistent with the capac-
ity of the BM to sustain long-term survival of plasma
cells, APRIL expression is at its highest in immature
myeloid cells within the BM [45]. As with BAFF, APRIL
expression is not limited to cells of myeloid origin, with
several studies detecting its expression in epithelial cells
of the gut [80,81], tonsil [32], breast [82], and skin [83].
APRIL expression may also be induced in cell cultures
of primary keratinocytes in response to various toll-like
receptor agonists [32].
Physiological role in immunity
In vivo studies in BAFF-deficient mice have shown that
BAFF signaling through BAFF-R is critical for the dif-
ferentiation of immature B cells to mature B cells start-
ing at the T1 stage, and for the survival of mature B
cells in subsequent stages [23,33–36]. A recent study has
reported a distinct subset of TACI-expressing transitional
B cells in wild type mice [84]. This subset is markedly
expanded in BAFF- transgenic mice and is characterized
by an activated phenotype expressing activation-induced
cytidine deaminase (AICD) and T-bet. Ex vivo stimula-
tion of these cells produces class-switched autoantibodies,
suggesting a potential role for TACI on transitional B cells
and humoral autoimmunity in high BAFF settings. BAFF
also appears to have a role in mature B cell responses;
in vitro studies indicate that, in the presence of IL-10 or
transforming growth factor-β , BAFF can induce CSR of
naïve B cells to an IgA isotype [37], and in vivo mouse
studies have confirmed that BAFF inducesCSR to IgG and
IgA via interaction with either BAFF-R or TACI [38,80].
The role of BAFF in the establishment of LLPCs is not
clear; while BAFF has been shown to support the sur-
vival of BMLLPCs in vitro and in vivo [39,40], plasmablast
transfer experiments indicate that establishment of a plas-
mablast population in the BM is not impaired in BAFF-
knock out (Ko) mice, suggesting that BAFF is not critical
for this process [43].
BAFFplays a part in T cell responses. Through its bind-
ing to BAFF-R, BAFF is able to activate sub-optimally
stimulated T cells [73,85,86], but impaired BAFF-BAFF-
R binding leads to prolonged allograft survival in mice
[87]. BAFF overexpression has been shown to augment
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type 1 T helper (Th1) responses in BAFF-transgenic (Tg)
mice [88], and BAFF signaling through BAFF-R promotes
the accumulation of follicular Th (Tfh) cells, autoantibody
production, and IFNγ production in BCMA-deficient,
lupus-pronemice. Furthermore, within the germinal cen-
ter (GC), Tfh cells have been shown to provide a local
source of BAFF, and are required for efficient selection
of high affinity GC B cells clones [89]. This evidence
supports the hypothesis that in SLE patients with high
BAFF, autoreactive B cells experiencing high affinity BCR
engagement may be rescued and retained during affinity
maturation due to local BAFF production. Elevated levels
of Tfh cells expressing BAFF-R but lacking BCMA were
observed in SLE patients [90]; a result that is interesting in
light of the observed correlation between circulating Tfh
cells and disease activity in SLE patients [91].
In addition to its role in immune activation, BAFFmay
also play a part in regulation of the immune response.
Exposure to BAFF in vitro and in vivo has been shown
to upregulate the expression of the immune suppressive
cytokine IL-10 by B regulatory cells in a TACI-dependent
manner, and IL-10 expression is abrogated by inhibition
of BAFF with TACI-Ig [92,93]. Interestingly, transient
increases in cell numbers from various B cell subsets have
been observed clinically in patients treated with BAFF
inhibitors [94–96]. This effect may reflect a reduced regu-
latory B cell response as a result of the inhibition of BAFF;
however, further study would be needed to confirm this.
Similarly, TACI may also possess some immune regula-
tory properties, as evidenced by TACI-Ko mouse mod-
els, which show increased B cell numbers compared with
wild-type mice [97]. Studies of collagen-induced arthritis
(CIA) inmice indicate that APRILmay have a similar reg-
ulatory role in humoral immunity: APRIL-Tg mice had
reduced disease severity and lower autoantibody titers
compared with control mice upon CIA induction [98].
However, to what extent APRIL transgene expression in
T cells reflects a physiological situation remains an open
question, especially in light of the observation that the
incidence of CIA in APRIL-Ko mice is decreased, rather
than increased [99]. More studies are warranted to deter-
mine under which conditions APRIL could stimulate or
dampen inappropriate immune responses.
As with BAFF, APRIL is a key player in the humoral
immune response, although it appears to act at a later
stage, modulating the function and survival of antigen-
experienced B cells [23,33–36]. Indeed, APRIL-deficient
mice do not display significant differences in immune sys-
tem development compared with wild-type mice [100].
APRIL is able to induce CSR of naive B cells to IgA
or IgG in the presence of IL-10 or TGFβ in vitro [37],
and APRIL-deficient mice have reduced serum levels of
IgA and impaired IgA antibody responses to T-dependent
and type 1 T-independent antigens [99,101]. Further-
more, levels of IgM are increased in APRIL-Tg mice,
which display both elevated T-dependent IgM responses
and type 2 T-independent IgM and IgG responses [102].
Although both BAFF and APRIL play a role in CSR, find-
ings from a study investigating the effects of both pro-
teins on activation-induced cytidine deaminase (AID), an
enzyme on which CSR is dependent, suggest that BAFF
and APRIL induce CSR in murine B cells by different
mechanisms. Whereas APRIL increases the expression
of both AID and the transcription factor HoxC4, which
induces AID expression, BAFF only upregulates expres-
sion of AID [41]. The differential roles of BAFF and
APRIL in CSR are also highlighted in another study in
which BAFF plus IL-10 was required for the differenti-
ation of IgG plasmablasts, but IgA plasmablast differen-
tiation was dependent on APRIL [42]. This same study
found that the binding of APRIL to CD138 on DCs from
SLE patients induced both CSR to IgA and plasmablast
differentiation.
Numerous studies have demonstrated that APRIL is
important formaintenance of the plasma cell pool. APRIL
has been shown to promote the survival of LLPCs in
mouse BM [39,40,45,77,103], where it provides signals
that are critical for the establishment of an IgG-secreting
plasmablast reservoir [43]. APRIL mRNA has also been
identified in mouse lymph nodes in response to alum-
precipitated protein, where higher expression correlated
with the presence of more mature plasma cells [104].
Ex vivo studies further indicate that APRIL is critical for
the survival of human plasma cells in MALT [32,45,105]
and the small intestine [80,106]. Furthermore APRIL, as
well as BAFF, has been shown to promote the differenti-
ation of naïve B cells into LLPC [107], and the differen-
tiation and proliferation of human memory B cells into
plasmablasts [46], indicating that it has a role in immune
activation as well as survival. Notably, development and
maintenance of the BM plasma cell pool in vivo can be
driven by either BAFF or APRIL, and therefore blockade
of both of these cytokines is required to prevent plasma
cell accumulation and survival [29,39].
Further to its direct role in antibody-mediated
responses, APRIL may also contribute to T cell-mediated
immunity. Transgenic mice studies suggest that APRIL
may be involved in T cell survival [102], and APRIL has
been shown to induce B cell antigen-presentation in vitro
in murine splenic B cells [44,108].
Little is known about the physiological role of BAFF-
APRIL heteromers. On the one hand, it appears certain
that when BAFF is included within a heteromer complex
it is markedly less active in terms of activating BAFF-
R and maintaining B cell homeostasis than when it is
not. In this respect, heteromer formation could be a
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mechanism to down-regulate BAFF activity. On the other
hand, both ABB and BAA seem competent to activate
TACI and BCMA, andmight have specific agonist actions
on these receptors [62].
The role of BAFF and APRIL in autoimmune disease:
Preclinical evidence
The involvement of BAFF and APRIL in the pathogenesis
of autoimmune diseases has been the subject of extensive
research. Preclinical evidence is primarily derived from
mouse models in which BAFF, APRIL, or their recep-
tors are either impaired or deleted, or overexpressed as
transgenes.
BAFF overexpression in the mouse induces B cell-
derived autoimmune diseases comparable to SLE and
IgAN in humans. Lupus-like disease manifestations that
are observed in BAFF-Tg mice include increased anti-ds-
DNA and anti-nuclear autoantibody (ANA) production,
increased renal Ig complex deposition, and raised serum
IgA, IgG and IgE levels [109,110]. IgA nephritis-like
manifestations such as increased mesangial IgA deposits
and raised levels of circulating aberrantly glycosylated
IgA coinciding with nephritis have also been observed
[13]. Interestingly, a number of investigations suggest
that BAFF alone is not sufficient to drive lupus-like dis-
ease; a study comparing the insertion of the BAFF Tg
into non-autoimmune-prone mice versus autoimmune-
prone mice found that only the latter developed fulmi-
nant renal pathology [111]. Similarly, when BAFF-Tg
was introduced into SLE-resistant mouse models, a lack
of significant renal immunopathology or active autoim-
mune disease was noted, even though IgG autoantibody
serum levels were increased [112]. BAFF deficiency in
New Zealand Mixed (NZM) spontaneous mouse mod-
els of SLE also resulted in disease attenuation but not
abrogation [113]. Although these animal studies suggest
a strong role for BAFF in the pathogenesis of antibody-
mediated autoimmunity, they imply that other factors are
required for the development of full-blown autoimmune
disease. Notably, T cell-deficient BAFF-Tg mice develop
an SLE-like disease that is essentially the same as that
observed in BAFF-Tg mice with functional T cells, sug-
gesting that BAFF-mediated autoimmunity develops in
a T-independent manner [114]. In one study, the SLE-
like symptoms observed in BAFF-Tg mice were totally
abrogated in the absence of TACI in the hematopoietic
compartment, without extensive loss of B cells [115], sug-
gesting that TACI activation, and not B cell activation
in general, is responsible for auto-antibody production.
If this also applies to clinical SLE, specific inhibition of
TACI might represent an alternative to ligand inhibition.
Also, inhibition of both TACI ligands would be predicted
to reduce the symptoms of SLE more efficiently than
inhibition of a single ligand. In contrast, a study using
BAFFR-Ko, TACI-Ko, BCMA-Ko NZM2328 mice found
that any single BAFF/APRIL receptor was dispensable for
the development of SLE [116]. During a subsequent study
conducted by the same group using NZM2328 mice defi-
cient in BAFF/APRIL receptor pairs, the authors con-
cluded selective targeting of BAFFR plus TACI or BAFFR
plus BCMA may be an efficacious approach [117]. These
findings show that the role of BAFF/APRIL receptors is
more complex than previously thought, although com-
pensatory mechanisms potentially taking place during
life-long deficiency of the receptor(s) cannot be excluded.
Although its role has been less extensively studied
in animal models, there is preclinical evidence to sup-
port a role for APRIL in antibody-mediated autoimmu-
nity. APRIL mRNA and protein expression is increased
in the BM of spontaneous mouse models of SLE com-
pared with control mice [118], and administration of
anti-APRIL antibody to mouse models of IgAN results
in decreased disease activity (as evidenced by reduced
IgA serum levels and reduced glomerular IgA complex
deposition) [119]. Studies of APRIL in mouse models of
CIA have reported conflicting findings on the effect of
APRIL on autoantibody production and arthritis severity.
Whereas one group found that IgG2a autoantibody lev-
els were significantly reduced following the subjection of
APRIL-deficientmice to CIA [99], another group demon-
strated that the severity of CIA was reduced in APRIL-Tg
mice alongside a decline in autoantibodies and immune
complex deposition, consistent with a protective effect of
APRIL against CIA [98]. Caution should be applied when
interpreting these findings, however, since the APRIL
transgene in this model was controlled by a T cell-specific
promoter, which is not consistent with the known pattern
of APRIL expression [102]. Clinical evidence supporting
a role for APRIL in human antibody-mediated autoim-
mune diseases ismore compelling, and is discussed below.
The role of BAFF and APRIL in autoimmune diseases:
Clinical evidence
SLE
Shortly after its identification and characterization as
a B cell-stimulating cytokine, elevated levels of func-
tional soluble BAFF were found in the sera of patients
with SLE compared with controls [4]. Increased expres-
sion of BAFF mRNA has also been observed in periph-
eral blood leukocytes, and increased expression of the
membrane-bound form has been found in PBMCs from
patients with SLE [5,6]. Numerous subsequent studies
have confirmed these findings and the presence of high
serum levels of BAFF in patients with SLE is now very
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well-established [1–3]. Several other studies of patients
with SLE have detected a correlation between increased
levels of serum BAFF and raised autoantibody levels,
specifically anti-ds-DNA [4,5,51] and anti-Smith anti-
bodies [3]. However, one recent study found no asso-
ciation between BAFF serum levels and anti-ds-DNA
autoantibody titers in patients with SLE; although the
authors suggest that the disrepancy between this finding
and previous reportsmay be due to different anti-ds-DNA
detection methods [1]. Indeed, the link between BAFF
and anti-ds-DNA has been demonstrated in mice, where
BAFF overexpression leads to the maturation of anti-ds-
DNA B cells [120].
Post-hoc analyses of the randomised phase III clinical
studies, BLISS-52 and BLISS-76, showed BAFF levels
2 ng/ml at screening to be an independent prognostic
factor for increased risk of moderate and severe lupus
flare [49]. Other SLE markers, including raised autoan-
tibody levels, were also associated with BAFF 2 ng/ml
[121]. Similarly, a post hoc analysis of the phase II/III
APRIL-SLE study also found that BAFF levels greater
than median at baseline correlated with increased risk of
British Isles Lupus Assessment Group (BILAG) A or B
flare in the placebo group [122]. Other studies investigat-
ing the association between BAFF serum levels and SLE
disease activity, however, have yielded mixed results. For
example, some investigators have reported correlations
between serum BAFF and SELENA–SLEDAI (Safety of
Estrogen in Lupus Erythematosus National Assessment
SLE Disease Activity Index) score [48] and the Mexican
(Mex)-SLEDAI score [2], while others have reported
a lack of correlation between BAFF and SLEDAI [1,5]
or the Systemic Lupus Activity Measure (SLAM) [4]. It
is feasible that the use of different scoring systems to
measure disease activity may have led to the discrepancy
between these findings; however, two different studies
both investigating the association between BAFF and the
Systemic Lupus International Collaborating Clinics/ACR
Damage Index (SLICC/ACR DI) have reported conflict-
ing outcomes [3,4]. These different observations may also
reflect the different methods used to detect BAFF; for
instance, one group demonstrated that increased BAFF
mRNA levels in PBMCs correlate better with disease
activity than serum BAFF protein [6]. Furthermore, it is
feasible that the use of BAFF to predict disease outcomes
needs to focus on more specific manifestions of SLE
rather than general disease activity, for example renal
pathology, since BAFF levels are higher in patients with
active lupus nephritis (LN) compared with controls [123].
Similar observations have been made for APRIL in
SLE, with multiple investigations reporting raised levels
of soluble APRIL in the sera of patients with SLE com-
pared with healthy individuals [7–10]. In addition to the
APRIL protein, an association between SLE and a poly-
morphism at codon 67 of the APRIL gene has also been
demonstrated [124,125]. There are conflicting reports for
correlations between APRIL serum levels and autoan-
tibodies in patients with SLE. Some investigators have
noted a weak correlation between elevated APRIL levels
[7] and anti-ds-DNA antibodies, while others have sug-
gested that an inverse correlation exists between the two
[8,9]. Like BAFF, APRIL levels in sera appear to be linked
to SLE disease activity. Although inverse correlations have
been observed between serum APRIL levels and SLEDAI
scores [8,9], a significant positive association has been
noted with the BILAG index overall [10], as well as spe-
cific manifestations of SLE, including the BILAG muscu-
loskeletal score [7,10], and the BILAG cardiorespiratory
score [10]. Associations have also been observed between
both serum APRIL levels and renal mRNA expression,
and renal disease severity in patients with LN, with raised
APRIL levels predictive of resistance to immunosuppres-
sive therapy [50].
Although both BAFF and APRIL are undoubtedly
raised in the sera of patients with SLE, a relationship
between co-expression of the two molecules is yet to be
clearly determined. In one study, a negative correlation
between BAFF and APRIL serum levels was observed [9].
A separate study found no correlation between serum
BAFF and APRIL, but mRNA levels of the two cytokines
was paralleled in the blood, leading the authors to suggest
that serum levels of the BAFF and APRIL proteins may
be differentially regulated [8]. Another investigation indi-
cated that abberant activation of B cells in patients with
SLE contributes to raised levels of both cytokines, which
may in turn lead to a vicious circle resulting in the fur-
ther up-regulation of BAFF and APRIL expression [126].
Furthermore, in the same post-hoc analysis of the APRIL-
SLE study that found an association between BILAG A
or B flare risk and BAFF, a more pronounced risk was
observed when both APRIL and BAFF were elevated in
tandem [127].
IgAN
Several investigators have reported raised levels of BAFF
protein in the sera of patients with IgAN compared
with controls [11–13]. In one study, an association was
found between BAFF serum levels and disease severity, as
measured by IgAN markers including renal histopathol-
ogy, estimated glomerular filtration rate, serum creati-
nine, circulating IgA1 levels, and mesangial IgA deposi-
tion density [11,12]. A number of additional studies have
shown that mononuclear cells isolated from the tonsils
of patients with IgAN can be induced to express higher
levels of BAFF in vitro than those from control patients
[128–130].
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Elevated serum levels of APRIL have also been
reported in patients with IgAN. In one study, APRIL lev-
els correlated with IgAN disease activity markers, serum
creatinine, and urine protein/creatinine ratio in a subset
of patients. Notably, raised BAFF levels in these patients
were modest in comparison to those of APRIL [13]. In
another study, APRIL protein was significantly higher in
the plasma of IgAN patients compared with healthy con-
trols, and increased plasma APRIL levels were associated
with more severe clinical manifestations (higher protein-
uria and lower glomerular filtration rate). Furthermore,
upregulation of APRIL mRNA expression was detected
in B cells derived from patients with IgAN and a trend
towards increasedBCMAandTACI expression compared
with controls was also observed [131].
Other antibody-mediated autoimmune diseases
In addition to SLE and IgAN, increased BAFF and APRIL
expression has been observed in other rheumatic diseases.
Elevated serum levels of BAFF protein have been seen in
patients with RA compared with healthy control individ-
uals [17], and a positive correlation has been observed
between BAFF and IgM rheumatoid factor titers, as well
as anti-cyclic citrullinated peptide autoantibody [52]. The
BAFF-871C>T polymorphism has also been found to
influence the outcome of treatment with the anti-CD20
antibody rituximab in RA [132]. APRIL-producing cells,
as well as secreted APRIL, have been detected in the syn-
ovial tissues of patients with RA [133], both BAFF and
APRIL mRNA expression has been observed in inflamed
synovial tissue [134], and an association has been noted
between serum BAFF and synovitis [52].
Raised levels of BAFF have been found in the sera of
patients with SS compared with controls [14], and shown
to correlate with autoantibody levels [53]. Increased
APRIL levels have also been detected in the serum of
patients with SS, although the investigators in this study
found no difference between patients and controls in
terms of serum BAFF levels [15]. In another study,
increased serum BAFF and APRIL were found to corre-
late with SS focus score and IgG levels, suggesting a possi-
ble association between BAFF and APRIL and SS disease
activity [16]. However, a separate investigation revealed
that APRIL was absent from the salivary gland lesions
of patients with SS [135]. Although these studies have
reported somewhat mixed findings, the evidence overall
points to a degree of involvement of both cytokines in SS.
In addition to the better-known rheumatic diseases,
raised BAFF and APRIL levels have also been detected
in patients with the recently recognized condition, IgG4-
related disease (IgG4-RD) [136]. The precise role of the
two cytokines in the pathogenesis of IgG4-RD is yet
to be defined, however, high levels of APRIL-producing
macrophages have been detected in IgG4-related kidney
disease [137], and inhibition of APRIL has been shown to
suppress disease progression in a mouse model [138].
Endogenous BAFF and APRIL deficiencymay provide
a rationale for targeting BAFF and APRIL in
autoimmune disease
Given their critical role in B cell-mediated autoimmunity,
targeting BAFF and APRIL in the treatment of diseases
such as SLE and IgAN is a rational approach to therapy.
Direct inhibition of these two molecules has the potential
to prevent engagement of their receptors, BAFF-R, TACI
and BCMA, and thus to prevent subsequent activation
of B cell-driven mechanisms, such as autoantibody pro-
duction, that contribute to the pathology of autoimmune
diseases.
The potential effects of impaired TACI signaling can
be seen endogenously in common variable immunodefi-
ciency (CVID), a disease characterized by hypogamma-
globulinemia and recurrent respiratory infections [139].
Mutations in the TACI gene, TNFRSF13B, can be
found in subsets of patients with CVID at a significantly
higher rate compared with healthy individuals. When
naïve B cells from such patients are exposed to APRIL
ex vivo, this does not lead to isotype switching, sug-
gesting that the TNFRSF13B mutation leads to impaired
APRIL-TACI signalling [140]. A similar observation was
made in a study of CVID patients with homozygous
TNFRSF13Bmutations, inwhich a reduced B cell prolifer-
ative response to IgM/APRIL costimlation was observed,
as well as defective IL-10-, APRIL- or BAFF-induced CSR
[141]. A large analysis of 564 unrelated patients confirmed
that two disease-modifying TACI mutations, C104R and
A181E, are significantly enriched inCVID, although these
were neither necessary nor sufficent to cause the disease
[142].
Genetic alterations in the BAFF-R gene, TNFRSF13C,
have also been found in CVID, including three polymor-
phic variants that result in amino acid substitutions, one
of which, P21R, interferes with BAFF-R self-association
and function, and contributes to CVID [143,144]. One
investigation reported two human siblings each carrying
a homozygous deletion in TNFRSF13C that deletes the
transmembrane domain of BAFF-R, leading to lack of
BAFF-R expression. These patients had a B cell matura-
tion arrest at the transitional stage, lower levels of serum
IgG and IgM, but normal IgA levels, leading the investi-
gators to conclude that abrogation of BAFF-R leads to an
altered immunological phenotype but not necessarily to
full-blown immunodeficiency [145].
Taken together, these findings suggest that impaired
TACI or BAFF-R signalling can lead to hypogammaglob-
ulinemia. Although this outcome is clearly not desirable
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when it manifests as CVID, these observations never-
theless imply that inhibition of TACI and/or BAFF-R
signaling has the potential to block the processes that
lead to autoantibody production in patients with humoral
autoimmune disease.
In addition to studies in CVID, recent investigations
have revealed the existence of soluble forms of TACI
and BCMA that are elevated alongside raised BAFF and
APRIL in patients with SLE. Soluble TACI (sTACI) has
been shown to bind BAFF and APRIL, whereas sol-
uble BCMA (sBCMA) only binds APRIL. sTACI and
sBCMA act as decoy receptors, blocking engagement
between BAFF and APRIL and membrane-bound TACI
and BCMA, resulting in inhibition of NF-κB signal-
ing by both receptors, and subsequent inhibition of B
cell survival in vitro [146,147]. These observations serve
to support the rationale for blockade of BAFF/APRIL
engagement with their receptors in order to reduce
their potential to promote the survival of pathogenic B
cells.
Preclinical investigation of BAFF/APRIL antagonists
in animalmodels of autoimmune disease
As part of the research to characterize the roles of BAFF
and APRIL in immunity and pathogenesis, the effects of
blocking the two cytokines have been investigated in ani-
mal models of autoimmune disease. These include pri-
marily NZM mice and NZB/W F1 mice, which sponta-
neously develop characteristics of SLE.
In one study, treatment of NZB/W F1 mice with a
BAFF-R fusion protein blocked BAFF signaling, result-
ing in reduced SLE disease activity [67]. In another
study, BAFF-deficiency in NZM.Baff−/− mice reduced
total Ig and autoantibody levels up to 4–6 months
of age, after which time autoantibody levels increased,
despite the complete absence of BAFF [113]. In these
autoimmunity-prone BAFF-deficient mice, proteinuria
and mortality rates were much decreased, indicating
that BAFF inhibition may be able to attenuate disease
severity, while not offering complete protection from
autoimmunity.
Treatment of NZB/W F1mice with anti-APRIL mon-
oclonal antibodies (mAbs) had a modest effect on dis-
ease progression and mortality [118]. Anti-ds-DNA IgG
were unaffected and anti-chromatin levels were mod-
estly decreased. By contrast, a previous study reported
an inverse correlation between APRIL serum levels and
anti-ds-DNA titers in patients with SLE [8]. Similar
results have been observed in IgAN mouse models, in
which treatment with anti-APRIL antibodies reduced dis-
ease progression, lowered serum IgA levels and reduced
glomerular deposition of immune complexes [119].
A number of studies suggest that dual inhibition
of BAFF and APRIL may provide more pronounced
pharmacodynamic (PD) effects than inhibition of either
molecule alone and may also be efficacious in SLE mod-
els. In an investigation comparing BAFF blockade by the
fusion protein BAFF-R-Ig with BAFF/APRIL blockade
by the TACI-Ig fusion protein, both techniques led to
a reduction of B cell numbers and prolonged survival
in NZB/W F1 mice, but only TACI-Ig led to reduced
IgM levels, inhibition of the IgM response, and reduced
plasma cell numbers in both spleen and BM in NZM2410
mice [148]. This is consistent with a separate investiga-
tion in which TACI-Ig treatment led to reduced survival
of plasma cells [40]. Therefore, TACI-Ig may be a bet-
ter option for disease mediated by short-lived or LLPC.
On the other hand, use of either BAFFR-Ig or TACI-Ig
may cause immunosuppression due to the mechanisms
of action. Clear understanding of the BAFFR-Ig or TACI-
Ig drug exposure, PD and disease treatment effect may
help to identify the dose range that will offer the best
risk benefit balance. When BAFF/APRIL-Ko mice were
compared with BAFF-Komice, impairment of both BAFF
and APRIL led to a more pronounced reduction in BM
plasma cells than impairment of BAFF alone [149]. No
increased modulation of disease phenotype was noted
with dual BAFF/APRIL deletion versus deletion of BAFF
alone, prompting the investigators to question whether
the efficacy achieved by the clinical targeting of both
molecules would be offset by the potentially detrimen-
tal effects of stronger immunosuppression. In terms of
the clinical application of BAFF and/or APRIL inhibition,
this concern is valid and warrants careful investigation.
However, it cannot be excluded that compensatory mech-
anisms potentially taking place during a life-long BAFF-
and APRIL-deficiency might differ from those achieved
upon pharmacological inhibition in BAFF- and APRIL-
sufficient animals. Our group has recently presented early
findings that show that pharmacological dual inhibition
of both BAFF and APRIL with TACI-Fc was able to com-
pletely prevent disease progression in NZB/W F1 mice,
with the onset of nephritis, autoantibody production and
glomerular immune complex deposition arrested [47]. By
contrast, inhibition of BAFF alone with BAFF-R-Fc was
only able to delay, but not prevent indefinitely, the devel-
opment of SLE. It is unlikely that these differences could
be explained by the activation of membrane-bound BAFF
or APRIL by TACI-Fc [150]. Interestingly, in vitro studies
have shown that BAFF/APRIL/APRIL heteromers can be
blocked by TACI-Ig and BCMA-Ig, but not by BAFF-R-
Ig or an anti-BAFF antibody [61,62], suggesting that dual
inhibition of BAFF/APRIL by TACI-Ig may be the only
effective method by which to block the BAFF/APRIL het-
eromers that are present in autoimmune diseases [60,61].
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Clinical investigation of BAFF and APRIL antagonists
in SLE and other humoral autoimmune diseases
Agents targeting BAFF signaling alone and BAFF/APRIL
signaling together have both been subject to clinical inves-
tigation. While BAFF signaling is targeted through direct
blockade of BAFF, BAFF/APRIL signaling inhibition has
been achieved using a soluble form of their shared recep-
tor, TACI. Soluble forms of BCMA have not yet been
explored in a clinical setting, probably because BCMA
has a higher affinity for APRIL than BAFF, whereas TACI
binds both molecules with similar affinity [63,64].
BAFF only inhibition
During recent years, a number of BAFF-targeting agents
have been explored in the treatment of SLE. Three
of these, belimumab (GlaxoSmithKline), blisibimod
(Anthera) and tabalumab (Eli Lilly), have reached phase
II/III clinical investigation.
Belimumab. Belimumab (Benlysta R©) is a recombi-
nant, fully human IgG1λ mAb that binds soluble BAFF,
blocking its interaction with BAFF-R, TACI and BCMA
[151]. An initial randomized phase I study in patients
with mild-to-moderate SLE confirmed the safety and
tolerability of belimumab and demonstrated its biological
activity through significant B cell reductions compared
with placebo [152]. A subsequent phase II study in 449
SLE patients failed to meet its co-primary endpoints
of improved SELENA-SLEDAI scores at week 24 and
delayed time to first flare up to week 52; however, a post
hoc analysis revealed improved disease activity with beli-
mumab in a subgroup of patients with serologically active
disease (ANAs  1:80 and/or anti-ds-DNA antibodies
30 IU/mL) at week 52. Reductions in naïve, activated
and plasmacytoid CD20+ B cells, as well as anti-ds-DNA
antibody titers were also observed [153]. Following
on from this positive finding, two large randomized
phase III studies, BLISS-52 (n = 867) and BLISS-76
(n= 819), examined belimumab 1 or 10mg/kg compared
with placebo for 52 weeks and 76 weeks, respectively, in
patients with seropositive (ANA+ or anti-ds-DNA+)
SLE [152,154]. While BLISS-52 demonstrated significant
improvements in the SLE Responder Index (SRI) at
both doses [154], improvements were only seen with the
higher belimumab dose in BLISS-76 [155]. No significant
imbalance of adverse events (AEs) were reported between
treatment arms in any of these studies. Based on these
findings, belimumab 10 mg/kg was approved in 2011 by
both the FDA and the EMA as an add-on therapy for
patients with active, autoantibody-positive SLE receiving
standard treatment.
Since receiving approval, the subcutaneous (s.c.)
administration of belimumab in patients with SLE has
also been investigated in the phase III BLISS-SC trial
(n = 839), which demonstrated increased SRI-4 response
at week 52 with belimumab 200 mg versus placebo
and a similar safety profile [156]. At the time of writ-
ing, several more phase III studies investigating beli-
mumab in autoimmune diseases are either ongoing or
planned. These include long-term extension studies fol-
lowing BLISS-52 and BLISS-76 (NCT00712933), a con-
tinuation of BLISS-SC in Northeast Asian and Japanese
patients (NCT0159762), a phase III study in Northeast
Asian patients with SLE (NCT01345253), a phase III
study in patients with LN (NCT01639339), and a phase
II/III study in patients with refractory idiopathic inflam-
matory myositis (NCT02347891).
Blisibimod. Unlike belimumab, which is reported to
target soluble BAFF, blisibimod is a peptibody that binds
both the soluble and membrane-bound forms of BAFF
[157]. Initial phase I studies confirmed the safety of blisi-
bimod in patients with mild SLE, and reductions in naïve
B cell numbers suggested a pharmacodynamic effect [94].
Subsequently, a phase IIb study of s.c. blisibimod (100
or 200 mg once-weekly [QW], or 200 mg every 4 weeks
[Q4W]) compared with placebo in patients with seropos-
itive SLE (PEARL-SC; n = 547), failed to meet its pri-
mary endpoint of improved SRI-5 response at week 24 in
the pooled dose group, but showed significant improve-
ments with the highest dose [158]. Significant reduc-
tions in anti-ds-DNA antibody titers, complement C3
and C4, and B cell numbers were observed with blisibi-
mod compared with placebo. No imbalances in AEs were
reported in either the phase I or phase II blisibimod stud-
ies [94,158]. At the time of writing, two randomized phase
III studies in patients with seropositive SLE, CHABLIS-
SC1 (NCT01395745) and CHABLIS7.5 (NCT02514967),
were ongoing and planned, respectively, and a further
phase II/III study in patients with IgAN, BRIGHT-SC
(NCT02062684) was also ongoing.
Tabalumab. Tabalumab is a human IgG4 mAb that,
like blisibimod, binds both forms of BAFF [159]. The
biological activity, safety and tolerability of tabalumab
was initially characterized in randomized phase II
trials in patients with RA. These studies showed
that there was no meaningful difference in AEs with
tabalumab compared with placebo, however, treat-
ment with tabalumab led to transient increases in
total B cells, as well as naïve and memory B cells
[95,96]. Efficacy signals in patients with RA were
mixed, with primary efficacy endpoints being met in
only one out of the three phase II studies [95,96,160].
Two pivotal phase III studies, ILLUMINATE-1
(n = 1164) and ILLUMINATE-2 (n = 1124), assess-
ing tabalumab in patients with moderate-to-severe
SLE were done. In ILLUMINATE-1, tabalumab did
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not achieve the primary endpoint (SRI-5), whereas in
ILLUMINATE-2, the higher frequency dosing regimen
of tabalumab (120 mg every 2 weeks) met this endpoint
[161,162]. In response to these results, the sponsor Eli
Lilly announced in 2014 that development of tabalumab
would be discontinued due to failure tomeet expectations
of efficacy [163].
BAFF and APRIL dual inhibition
Atacicept. To date, the most extensively investigated com-
pound targeting soluble and membrane-bound forms
of both BAFF and APRIL is atacicept. Atacicept is a
fully human, recombinant soluble fusion protein con-
taining the extracellular ligand-binding domain of TACI
fused to a modified Fc portion of human IgG1, which
is designed to be administered via s.c. injection. The
safety, tolerability and biological activity of atacicept were
confirmed in phase Ib placebo-controlled dose escalation
trials in patients with mild-to-moderate SLE [164,165].
Atacicept was subsequently investigated in the treatment
of RA in two phase II studies, which compared atacicept
doses up to 150 mg with placebo in patients for whom
TNF-antagonist treatment had failed (AUGUST-1;
n = 256), and in TNF-antagonist-naïve patients
(AUGUST-2; n = 311) [166]. Both studies failed to
meet their primary endpoints of 20% improvement in
disease severity according to ACR criteria at week 26,
but were able to further confirm the biological activity
of atacicept by showing dose-dependent reductions in
IgM, IgA and IgG levels, as well as absolute reductions in
mature B cells and plasma cells relative to baseline at week
26. An additional exploratory phase II study (AUGUST-3;
n = 27) demonstrated reduced median Ig levels at week
32 compared with baseline, but showed no additional
clinical benefit of adding atacicept to rituximab [167].
The APRIL-SLE phase II study, which examined ataci-
cept 75 or 150mg compared with placebo in patients with
moderate-to-severe SLE, yielded more promising efficacy
results [122]. In post hoc analyses, atacicept 150mgweekly
(add-on to standard of care) was associated with a reduc-
tion in risk of flare (defined as a BILAG A or B flare,
with discontinuations imputed as flares). However, this
treatment arm was discontinued prematurely following
a second infection-related death, in accordance with the
recommendation from the Independent DataMonitoring
Committee. The primary endpoint, evaluating the risk of
flare in patients treated with atacicept 75 mg weekly ver-
sus placebo (add-on to standard of care), was not met.
Both atacicept doses were also associated with reductions
in B cells, plasma cells, total Ig levels and anti-ds-DNA
antibodies, and increases in complement C3 and C4 lev-
els. As might be expected given the PD effect of ataci-
cept on the immune system, the most frequently reported
serious AE noted in the APRIL-SLE study was infection.
However, serious infection occurred at a similar incidence
with atacicept 75 and 150 mg and placebo (8.3%, 7.6%
and 7.1%, respectively) [122], and at a comparable rate
to that reported with the BAFF-only inhibitor belimumab
1 and 10 mg/kg in the BLISS 76 (7.0 and 7.3%, respec-
tively) [155] and BLISS-52 (8% and 4%, respectively)
[154] studies. The majority of AEs with atacicept were
mild or moderate. The two fatalities (1.4%) that were
reported in the atacicept 150 mg treatment arm were
caused by acute respiratory failure secondary to possi-
ble leptospirosis, and pneumococcal pneumonia and alve-
olar hemorrhage secondary to lupus [122], but neither
were associatedwith hypogammaglobulinemia. Although
inter-study comparisons should be treated with caution,
similar numbers of deaths occurred in the belimumab-
treatment groups in the BLISS-76 and BLISS-52 trials (3
[0.6%] and 6 [1.0%]), with 3 of the deaths occurring in
BLISS-52 attributed to infection [154,155].
A phase II/III study assessing the safety and efficacy
of atacicept 150 mg in patients with active LN receiving
newly initiated corticosteroids (CS) and mycophenolate
mofetil (MMF), was stopped after the enrollment of six
patients due to increased infections associated with an
unexpected decline in serum IgG. A number of factors
likely contributed to these adverse events [168]. These
are discussed in further detail in a review by Cogollo
et al. [169], however, in summary the IgG decline began 2
weeks prior to first administration of atacicept, when CS
and MMF therapy was initiated, and continued after the
addition of atacicept. Since these standard therapies have
been linked to hypogammaglobulinemia in other studies,
they may have contributed to the reduced IgG observed
in the atacicept study [169]. Subsequent to the discontin-
uation of the phase II/III study, a phase Ib study examin-
ing the safety and tolerability of atacicept in patients with
LN receiving a stable regimen of MMF with glucocorti-
coids was undertaken. This trial was also terminated pre-
maturely, following the death of the first patient enrolled.
The post-mortem examination revealed that the cause of
death, cardiac failure due to an acute thrombus in the left
anterior descending artery, occurred in the setting of pre-
existing diffuse coronary artery disease associated with
cardiac ischemic changes of at least several weeks’ dura-
tion, prior to the administration of atacicept.
The safety and tolerability of atacicept has now been
studied in >1000 patients. Further evaluation of the ben-
efit risk profile of ataciept in patients withmoderate SLE is
being evaluated in the phase IIb clinical study, ADDRESS
II (NCT01972568). The primary endpoint of ADDRESS
II is the proportion of patients achieving reduced disease
activity (defined by meeting the SLE Responder Index
Criteria; SRI), with atacicept 75 or 150mg versus placebo,
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at 24 weeks. At the time of writing, enrollment was
complete, with the primary analysis due to be carried out
in 2016. A long-term extension study of ADDRESS II
will assess the long-term safety, effects on disease activity,
and PD effects such as levels of serum Ig, B cells, and
plasma cells. The study will also examine the correlation
between baseline serum levels of BAFF and APRIL with
treatment response (NCT02070978). Based on its proven
pharmacodynamics effects, future clinical exploration
of atacicept in other antibody-mediated autoimmune
diseases is warranted.
RCT-18. Another compound targeting both BAFF and
APRIL is the TACI RCT-18-Fc recombinant fusion pro-
tein, RCT-18, which contains a longer TACI fragment
than atacicept. RCT-18 was recently assessed in a ran-
domized phase I, first-in-man study in patients with RA
(n = 28) [170]. Compared with placebo, RCT-18 was
found to be well-tolerated when administered s.c. at doses
up to 540 mg, with IgM reductions achieved at the high-
est dose. However, no difference between RCT-18 and
placebo in terms of IgG or IgM response profiles was
found. RCT-18 has also been investigated in a small phase
I study in which patients (n = 12) were randomized
3:1 to receive RCT-18 (180 mg s.c. QW) for 4 weeks or
placebo, and observed for 84 days [171]. The investigators
reported reductions in IgM and IgA levels, but increases
in naïve and memory B cell counts after administration.
A higher rate of infection was also observed amongst
patients receiving RCT-18, leading the investigators to
conclude that a lower dose should be considered for future
studies.
APRIL and BAFF as predictive biomarkers
Post-hoc analyses of the BLISS study have suggested a link
between treatment response to belimumab and increased
baseline serum levels of BAFF. Response parameters were
numerically higher in patients with BAFF2 ng/ml com-
pared with those with BAFF <2 ng/mL [121], suggesting
that baseline BAFFmay be a usefulmeasure for predicting
response to belimumab treatment in the future. Similarly,
a post-hoc analysis of the APRIL-SLE study has indicated
that treatment effect size was greatest in a subgroup of
patients with high baseline serum levels of both BAFF and
APRIL, suggesting a role for the concurrently increased
expression of these cytokines as a predictive biomarker for
atacicept [172].
While these observations represent an exciting
prospect for the use of APRIL and/or BAFF serum
levels as predictive biomarkers, it is worth highlighting
that several factors need to be taken into consideration
for potential future techniques utilizing the two cytokines
to identify patients most likely to respond to belimumab
or atacicept treatment. For example, circulating BAFF
and/or APRIL are not necessarily active molecules due to
their potential to be blocked by soluble decoy forms of
BCMAandTACI [146,147]. Furthermore, soluble BCMA
and TACI decoy receptor binding has the potential to
affect the quantification of BAFF andAPRIL levels. Few, if
any, studies have assessed whether the measured levels of
BAFF and APRIL represent active or inactive cytokines.
It is also unclear what proportion of BAFF and APRIL
are bound by BCMA, TACI, BAFF-R or HSPGs outside
the circulation (e.g. within the BM, MALT or gut) and
are therefore not detectable within the serum. Finally, the
correlation between treatment response and the relative
ratios of BAFF/APRIL homo- and heterotrimers in the
circulation may also be an influential factor that warrants
further examination.
Conclusion
TNF family members BAFF and APRIL have both over-
lapping and distinct roles in humoral immunity. Both
molecules play key roles in the pathogenesis of dis-
eases with autoreactive B cell involvement, such as SLE,
making them excellent candidate targets for new thera-
pies. Although the BAFF inhibitor belimumab is already
approved for the treatment of patients with SLE, emerging
evidence suggests that targeting both molecules may pro-
videmore complete inhibition of the processes involved in
autoantibody production. As such, studies are currently
ongoing to assess the safety and efficacy of the TACI-Ig,
atacicept, in the treatment of SLE, and the results of the
phase II ADDRESS II study are likely to be highly rele-
vant to the clinical community.
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